Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 101 clinical trials
Jaktinib Hydrochloride for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

This phase IIB, open-label, multicenter study evaluated the efficacy and safety of oral Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis and Previously Treated

colony stimulating factor
conjugated bilirubin
neutrophil count
anemia
direct bilirubin
  • 22 views
  • 24 Jun, 2021
  • 1 location
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.

  • 0 views
  • 01 Apr, 2021
  • 6 locations
Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

This phase II trial investigates how well elotuzumab works in treating patients with JAK2-mutated myelofibrosis. Elotuzumab may help to control myelofibrosis and/or help to improve blood cell

  • 0 views
  • 01 Mar, 2021
  • 1 location
Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors (ESSENTIAL)

This is a phase II, open label, prospective, single-arm study evaluating the efficacy and safety of selinexor in patients with PMF or secondary MF (PPV-MF or PET-MF) who are refractory or intolerant to ruxolitinib and/or any other experimental JAK1/2 inhibitors.

gm-csf
platelet transfusion
eltrombopag
granulocyte colony stimulating factor
platelet transfusions
  • 13 views
  • 25 May, 2022
  • 1 location
  • 0 views
  • 17 Jun, 2022
  • 1 location
  • 0 views
  • 01 Apr, 2021
  • 2 locations
Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm

This phase II trial studies how well ruxolitinib phosphate and azacytidine work in treating patients with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm. Ruxolitinib

myeloproliferative disorder
mds/mpn-u
mds/mpd
essential thrombocythemia
myelodysplastic/myeloproliferative neoplasms
  • 225 views
  • 22 Jan, 2022
  • 1 location
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

This is a phase I, open-label, dose-escalation study to determine the MTD of selumetinib when combined with the standard dose of azacitidine. Treatment will begin within 28 days of screening procedures. Treatment will continue indefinitely, provided that the patient continues to derive benefit. A patient will be taken off study …

chronic myelomonocytic leukemia
myelodysplastic/myeloproliferative neoplasms
conjugated bilirubin
anemia
polycythemia vera
  • 14 views
  • 25 May, 2022
  • 1 location
A Study of LNK01002 in Patients With Primary (PMF) or Secondary Myelofibrosis (PV-MF ET-MF) or Acute Myeloid Leukemia

This multicenter, open-label, phase 1 study designed to evaluate safety and tolerability of multi-kinase inhibitor LNK01002 in patients with primary myelofibrosis (MF), or MF due to polycythemia

refractory acute myeloid leukemia (aml)
  • 0 views
  • 17 Jun, 2021
  • 3 locations
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

and NSCLC 2nd/3rd line) and ruxolitinib (Part B Primary Myelofibrosis)

cancer
pemetrexed
  • 2 views
  • 03 Jun, 2022
  • 3 locations